Selexis Announces License Renewal With Diosynth Biotechnology

Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable significantly improved drug discovery, development, and cGMP production, announced that it has executed a license renewal agreement with Diosynth RTP Inc. (“Diosynth”), allowing for Diosynth’s continued access to the SURE Technology Platform, which includes the Selexis Genetic Elements.
PR Newswire